Key result
Endocalyx Pro reduces perfused boundary region by ~0.18 μm in postmenopausal females versus older males.
Why the study?
Endothelial glycocalyx thickness declines with age, but sex differences in glycocalyx thickness and responses to glycocalyx-targeted therapies remain unclear.
Does Endocalyx Pro oral supplementation improve endothelial glycocalyx thickness in older adults, and are there sex differences in the response?
RCT (n=22)
Placebo-controlled
Randomized
No
Does Endocalyx Pro oral supplementation improve endothelial glycocalyx thickness in older adults, and are there sex differences in the response?
Absolute Event Rate: -0.178% vs 0.087%
p-value: p=0.009
Postmenopausal females exhibit smaller endothelial glycocalyx thickness than older males, potentially related to BMI, and demonstrate a greater improvement with Endocalyx Pro supplementation.
Indicates potential benefit limited to postmenopausal females; extends RCT evidence on sex-specific glycocalyx responses in older adults.
Endothelial glycocalyx thickness declines with age, potentially increasing cardiovascular disease risk. However, sex differences in glycocalyx thickness and responses to glycocalyx-targeted therapies remain unclear. This post hoc analysis examined sex differences in glycocalyx thickness and the effects of Endocalyx Pro supplementation in older adults. We analyzed data from 22 participants in a prior clinical trial (NCT06071728) that assessed 12-week Endocalyx Pro (3712 mg/day) supplementation on vascular function. Glycocalyx thickness was estimated as the perfused boundary region (PBR) using the GlycoCheck, with higher PBR indicating smaller glycocalyx thickness. Postmenopausal females had higher PBR 4-25 than older males (2.11 ± 0.14 vs. 1.97 ± 0.13 μm; p = 0.02), particularly in microvessels 9-17 μm in diameter. Male sex (B [95% CI], -0.14 [-0.26, -0.02]; p = 0.02) and body mass index (BMI) (B [95% CI], -0.02 [-0.04, -0.01]; p = 0.01) were associated with lower PBR 4-25 in univariate analyses; however, when included in a multivariate model, the association with sex was attenuated (p = 0.15), while BMI remained significant (p = 0.04). After 12 weeks of Endocalyx Pro, PBR 4-25 increased in older males (+0.087 ± 0.148 μm) but decreased in postmenopausal females (-0.178 ± 0.148 μm; p = 0.009). In conclusion, we observed that postmenopausal females had smaller glycocalyx thickness, partially explained by BMI, and demonstrated a greater improvement with Endocalyx Pro, suggesting sex-specific therapy effects.
No takes yet. Share an insight, caveat, or question.
Gimblet et al. (2025) conducted an RCT in Aging (n=22). Endocalyx Pro vs. Placebo was evaluated on Change in perfused boundary region (PBR 4-25) in postmenopausal females vs older males receiving Endocalyx Pro (p=0.009). After 12 weeks of Endocalyx Pro supplementation, postmenopausal females demonstrated a significant reduction in PBR 4-25 (-0.178 μm) compared to an increase in older males (+0.087 μm, p=0.009).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: